-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s PEG-Endo
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's PEG-Endo report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Idiopathic Short Stature
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPEG-Somatropin in Idiopathic Short Stature report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPEG-Somatropin in Idiopathic Short Stature Drug Details: YPEG-somatropin is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCT-100 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCT-100 in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCT-100 in Sarcomas Drug Details: BCT-100 (PEG-BCT-100) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCT-100 in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCT-100 in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCT-100 in Neuroblastoma Drug Details: BCT-100 (PEG-BCT-100) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCT-100 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCT-100 in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCT-100 in High-Grade Glioma Drug Details: BCT-100 (PEG-BCT-100) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Turner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPEG-Somatropin in Turner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPEG-Somatropin in Turner Syndrome Drug Details: YPEG-somatropin is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCT-100 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCT-100 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCT-100 in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2b LA in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2b LA in Myelofibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2b LA in Myelofibrosis Drug Details: Ropeginterferon alpha-2b (Besremi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) Drug...